scholarly journals Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications

2019 ◽  
Vol 110 (6) ◽  
pp. 477-488 ◽  
Author(s):  
Shaojian Lin ◽  
Anke Zhang ◽  
Xun Zhang ◽  
Zhe Bao Wu
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Neuroendocrine Tumours ◽  
Clinical Use ◽  
Line Treatment ◽  
First Line ◽  
Hormone Production ◽  
Tumour Shrinkage ◽  
Pancreatic Neuroendocrine Tumours ◽  
First Line Treatment

Cabergoline is a dopamine agonist that has been used as the first-line treatment option for prolactin-secreting pituitary adenomas for several decades. It not only suppresses hormone production from these prolactinomas, but also causes tumour shrinkage. Recent studies revealed some novel mechanisms by which cabergoline suppresses tumour cell proliferation and induces cell death. In this article, we review the most recent findings in cabergoline studies, focusing on its anti-tumour function. These studies suggest the potential broader clinical use of cabergoline in the treatment of other tumours such as breast cancer, pancreatic neuroendocrine tumours, and lung cancer.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

2017 ◽  
Vol 49 (5) ◽  
pp. 568-571
Author(s):  
Côme Lepage ◽  
Laetitia Dahan ◽  
Nadia Bouarioua ◽  
Christos Toumpanakis ◽  
Jean-Louis Legoux ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Neuroendocrine Tumours ◽  
Line Treatment ◽  
First Line ◽  
Pancreatic Neuroendocrine Tumours ◽  
First Line Treatment

scholarly journals Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy

Endocrine ◽  
2021 ◽  
Author(s):  
Harald Lahner ◽  
Annie Mathew ◽  
Anna Lisa Klocker ◽  
Nicole Unger ◽  
Jens Theysohn ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Neuroendocrine Tumours ◽  
Cox Regression ◽  
Univariate Analysis ◽  
Objective Response ◽  
Line Treatment ◽  
First Line ◽  
Pancreatic Neuroendocrine Tumours ◽  
Well Differentiated ◽  
First Line Treatment

Abstract Purpose The role of streptozocin-based chemotherapy (STZ CTx) in advanced, well-differentiated pancreatic neuroendocrine tumours (PanNET) and the best sequence of treatments in advanced PanNET are unclear. We examined the outcomes after STZ CTx in patients who had been selected according to the current therapeutic guidelines. Methods Data from 50 PanNET patients consecutively treated with STZ CTx between 2010 and 2018 were analysed. The endpoints of the study were the objective-response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results STZ CTx was the first-line treatment in 54% of patients. The PanNET grades were as follows: 6% G1, 88% G2, and 6% well-differentiated G3. The ORR was 38%. Stable disease was the best response in 38% of patients and 24% showed progressive disease. Treatment was discontinued because of toxicity in one patient. Median PFS and OS were 12 (95% confidence interval (CI), 8.5–15.5) and 38 months (95% CI, 20.4–55.6), respectively. In the Kaplan-Meier analysis, the median OS was 89 months (95% CI, 34.9–143.1) for STZ CTx as first-line therapy compared with 22 months (95% CI, 19.3–24.7; p = 0.001, log-rank test) for subsequent lines. Bone metastases negatively impacted survival (HR, 2.71, p = 0.009, univariate analysis, HR, 2.64, p = 0.015, multivariate analysis, and Cox regression). Conclusions In patients selected according to current guidelines, PFS, and OS after STZ CTx were lower than previously reported, whereas ORR was unchanged. First-line treatment was positively associated with OS and the presence of bone metastases was negatively associated with OS. Pre-treatment with targeted or peptide-receptor radionuclide therapy did not alter ORR, PFS, or OS.

Sign in / Sign up

Export Citation Format

Share Document